Alnylam Pharmaceuticals, Inc.
RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
Last updated:
Abstract:
The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.
Status:
Application
Type:
Utility
Filling date:
9 Jan 2020
Issue date:
8 Oct 2020